This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feuillan, P. P. Articles by Cutler, G. B. Search for Related Content PubMed PubMed Citation Articles by Feuillan, P. P. Articles by Cutler, G. B., Jr.

Boys with Precocious Puberty Due to Hypothalamic Hamartoma: Reproductive Axis after Discontinuation of Gonadotropin-Releasing Hormone Analog Therapy

Developmental Endocrinology Branch, Warren Grant Magnuson Clinical Cener, National Institutes of Health, Bethesda, Maryland 20892

Address correspondence and requests for reprints to: Penelope P. Feuillan, M.D., Developmental Endocrinology Branch, Warren Grant Magnuson Clinical Cener, National Institutes of Health, Bethesda, Maryland 20892.

Hypothalamic hamartoma is an important cause of precocious puberty in boys. Although the GnRH analogs are known to be effective therapy, there are few studies of the recovery of the pituitary-gonadal axis following long-term treatment. To this end, we studied 11 boys with HH after 8.8 ± 3.2 yr (range, 4.0–12.6) of treatment with the GnRH agonist D-Trp⁶,Pro⁹,NEt-LHRH. The patients’ levels of LH and FSH, testosterone, testis volume, and body mass index were compared with those of six normal boys in pubertal stage IV–V. We found that the patients’ mean ± SD peak GnRH-stimulated LH and FSH had returned to the normal range by 1 yr after stopping therapy. Whereas testosterone returned to normal levels by 1 yr, the patients’ testis volume remained smaller than normal until 2 yr after therapy. Ultrasonography revealed diffuse, punctate, echogenic foci in the testicular parenchyma of two patients; these were first observed during GnRH agonist therapy and persisted unchanged after discontinuation of treatment. Neither of these two patients reported pain or testicular discomfort, no mass or irregularity was detected by manual examination in either patient at any time, and levels of ß-hCG and 1-fetoprotein were normal. By 4 yr after therapy, all patients had pubertal stage V pubic hair; their body mass index was not different from that of the normal boys at any time point. The dimensions of the patients’ hamartomas did not change during or after therapy, and no patient reported new neurological symptoms or signs suggestive of an enlarging lesion at any time during or after discontinuation of treatment. Two families did report episodes of emotional lability and truancy as the patients reentered puberty after discontinuation of treatment.

This article has been cited by other articles:

				J.-C. Carel, E. A. Eugster, A. Rogol, L. Ghizzoni, M. R. Palmert, and on behalf of the members of the ESPE-LWPES GnRH An Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children Pediatrics, April 1, 2009; 123(4): e752 - e762. [Abstract] [Full Text] [PDF]